Lipid Nanoparticle Manufacturing Market: Services and Technologies, 2023-2035 - Distribution by Type of Lipid Nanoparticle (Solid Lipid Nanoparticles and Nanostructured Lipid Carriers), Type of Molecule Delivered (Nucleic Acids, Small Molecules, Proteins/Peptides and Others), Company Size (Very Large and Large, Mid-sized and Small), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Blood Disorders, Rare Diseases and Other Disorders), Type of End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Other End-users) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts
The global lipid nanoparticle manufacturing market is expected to reach USD 0.66 billion in 2023 anticipated to grow at a CAGR of 11.8% during the forecast period 2023-2035.
In recent years, the pharmaceutical industry has seen substantial growth, marked by a rising number of drugs undergoing approval processes or exploration in preclinical studies and clinical trials. However, a persistent challenge in drug development remains the poor water solubility and bioavailability of many compounds. Around 90% of drugs in development and approximately 40% of existing pharmacological products face issues related to solubility or permeability. These challenges often result in premature elimination from the body before effective absorption, impacting their efficacy. As a result, pharmaceutical companies are actively seeking solutions to overcome these hurdles. Among various strategies to improve the solubility and bioavailability of therapeutic agents, lipid nanoparticles (LNPs) and similar lipid-based additives have garnered considerable attention from drug developers. LNPs are considered a versatile platform in nanomedicine delivery due to their ability to encapsulate diverse molecules and provide controlled drug release. Alongside the advancements in this field, the knowledge base regarding the use of LNPs in drug delivery has also expanded.
However, manufacturing lipid nanoparticles is a complex and costly process that requires diverse expertise. Consequently, pharmaceutical firms are increasingly turning to specialized contract manufacturing organizations (CMOs) equipped with the necessary technology and expertise to address technical and operational challenges. Outsourcing to such service providers allows sponsors to leverage innovative LNP technologies and gain operational flexibility. With inherent advantages like small size, multifunctional properties, and customizable surfaces, the market for LNP-based therapeutics is expected to grow significantly in the near future. This growth will consequently lead to an expansion in the lipid nanoparticle manufacturing market in the projected period.
Report Coverage
In recent years, the pharmaceutical industry has seen substantial growth, marked by a rising number of drugs undergoing approval processes or exploration in preclinical studies and clinical trials. However, a persistent challenge in drug development remains the poor water solubility and bioavailability of many compounds. Around 90% of drugs in development and approximately 40% of existing pharmacological products face issues related to solubility or permeability. These challenges often result in premature elimination from the body before effective absorption, impacting their efficacy. As a result, pharmaceutical companies are actively seeking solutions to overcome these hurdles. Among various strategies to improve the solubility and bioavailability of therapeutic agents, lipid nanoparticles (LNPs) and similar lipid-based additives have garnered considerable attention from drug developers. LNPs are considered a versatile platform in nanomedicine delivery due to their ability to encapsulate diverse molecules and provide controlled drug release. Alongside the advancements in this field, the knowledge base regarding the use of LNPs in drug delivery has also expanded.
However, manufacturing lipid nanoparticles is a complex and costly process that requires diverse expertise. Consequently, pharmaceutical firms are increasingly turning to specialized contract manufacturing organizations (CMOs) equipped with the necessary technology and expertise to address technical and operational challenges. Outsourcing to such service providers allows sponsors to leverage innovative LNP technologies and gain operational flexibility. With inherent advantages like small size, multifunctional properties, and customizable surfaces, the market for LNP-based therapeutics is expected to grow significantly in the near future. This growth will consequently lead to an expansion in the lipid nanoparticle manufacturing market in the projected period.
Report Coverage
- The report comprehensively examines the lipid nanoparticle manufacturing market, categorizing it by type of lipid nanoparticle, type of molecule delivered, company size, target therapeutic area, type of end-user and key geographical regions
- It analyzes market growth factors (such as drivers, restraints, opportunities, and challenges) and assesses potential advantages and obstacles faced by stakeholders. The report also delves into the competitive landscape among top market players.
- Revenue forecasts for market segments are provided concerning four major regions. The study employs a comprehensive methodology encompassing assumptions, methodologies, and quality control measures to ensure accuracy and reliability of findings.
- Historical trends, currency fluctuations, foreign exchange impact, recession, and inflation measurements are considered as influential factors shaping the lipid nanoparticle manufacturing market.
- A high-level overview is presented, capturing the current state and potential evolution of the lipid nanoparticle manufacturing market in the medium to long term.
- The report explores lipids, their types, advantages, applications in pharmaceuticals, formulation challenges, and the increasing necessity for outsourcing manufacturing operations.
- Evaluation criteria include establishment year, company size, headquarters location, manufacturing facility location, operational scale, delivered molecule types, therapeutic areas, and additional services offered.
- Assessment parameters cover formulation methods, molecule types, compatible dosage forms, administration routes, therapeutic areas, establishment year, company size, headquarters location, business models, and active market players.
- Examination criteria involve establishment year, company size, headquarters location, manufacturing facilities, operational scale, lipid types, product types, additional services offered, and competitiveness analysis.
- Comparative analysis of lipid nanoparticle contract manufacturing organizations is conducted based on company strength, service quality, and the number of manufacturing facilities.
- In-depth analysis is provided based on developer strength, technological aspects, and applicability in therapeutic areas.
- Detailed profiles of key players in LNP manufacturing services and technology are presented, including company overviews, portfolios, recent developments, and future outlooks.
- The report evaluates partnerships among stakeholders since 2019, considering various parameters and regional distribution of involved companies.
- An assessment is made regarding potential partnerships between mRNA vaccine and therapeutics developers and lipid nanoparticle manufacturers, considering multiple criteria.
- Detailed exploration of factors influencing companies' decisions to outsource LNP manufacturing or develop in-house capabilities is provided.
- Analysis of global installed capacity among LNP contract manufacturers is conducted based on company size, operational scale, and geographical distribution.
- Identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges impacting lipid nanoparticle manufacturing market growth.
- Acuitas Therapeutics
- Ascendia Pharmaceuticals
- Avanti Polar Lipids
- BIOVECTRA
- CordenPharma
- Creative Biolabs
- Curapath
- Curia
- Emergent Biosolutions
- EUROAPI
- Evonik
- Formumax Scientific
- Fresinius Kabi
- Fujifilm
- Integrated Nanotherapeutics
- leon-nanodrugs
- Matinas BioPharma
- Merck
- Pantherna Therapeutics
- Precision NanoSystems
- TLC Biosciences
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Lipids
5.3 Introduction to Lipid Nanoparticles
5.3.1. Types of Lipid Nanoparticles
5.3.1.1. Solid Lipid Nanoparticles
5.3.1.2. Nanostructured Lipid Carriers
5.3.2. Advantages of Lipid Nanoparticles
5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
5.3.3.1. Cancer Treatment
5.3.3.2. Gene Therapy
5.3.3.3. Vaccine Development
5.3.3.4. Medical Imaging / Diagnostics
5.3.3.5. Additional Applications
5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
5.6. Concluding Remarks
6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
6.2.1 Analysis by Year of Establishment
6.2.2 Analysis by Company Size
6.2.3 Analysis by Location of Headquarters
6.2.4 Analysis by Company Size and Location of Headquarters
6.2.5 Analysis by Location of Lipid Nanoparticle Manufacturing Facility
6.2.6 Analysis by Scale of Operation
6.2.7 Analysis by Type of Molecule Delivered
6.2.8 Analysis by Therapeutic Area
6.2.9 Analysis by Type of Additional Services Offered
7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE
7.1. Chapter Overview
7.2. Lipid Nanoparticle: Technology Landscape
7.2.1. Analysis by Type of Formulation Method
7.2.2. Analysis by Type of Molecule Delivered
7.2.3. Analysis by Compatible Dosage Form
7.2.4. Analysis by Routes of Administration
7.2.5. Analysis by Therapeutic Area
7.3. Lipid Nanoparticle Technologies: List of Technology Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Analysis by Business Model
7.3.6. Most Active Players: Analysis by Number of Technologies
8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE
8.1. Chapter Overview
8.2. Other Types of Lipids: List of Service Providers
8.2.1 Analysis by Year of Establishment
8.2.2 Analysis by Company Size
8.2.3 Analysis by Location of Headquarters
8.2.4 Analysis by Company Size and Location of Headquarters
8.2.5. Analysis by Location of Manufacturing Facility
8.2.6. Analysis by Scale of Operation
8.2.7 Analysis by Type of Lipid Manufactured
8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
8.2.9. Analysis by Type of Product
8.2.10. Analysis by Type of Additional Services Offered
8.2.11. Analysis by Type of Product and Type of Additional Services Offered
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
9.4.1. Company Competitiveness Analysis: Small Players
9.4.2. Company Competitiveness Analysis : Mid-sized Players
9.4.3. Company Competitiveness Analysis : Large and Very Large Players
10. TECHNOLOGY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
10.4.1. Technology Competitiveness Analysis: Players based in North America
10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific
11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES
11.1. Chapter Overview
11.2. Curia
11.2.1. Company Overview
11.2.2. Service Portfolio
11.2.3. Recent Developments and Future Outlook
11.3. Emergent BioSolutions
11.3.1. Company Overview
11.3.2. Service Portfolio
11.3.3. Recent Developments and Future Outlook
11.4. EUROAPI
11.4.1. Company Overview
11.4.2. Service Portfolio
11.4.3. Recent Developments and Future Outlook
11.5. Evonik
11.5.1. Company Overview
11.5.2. Service Portfolio
11.5.3. Recent Developments and Future Outlook
11.6. Ardena
11.6.1. Company Overview
11.6.2. Service Portfolio
11.7. BIOVECTRA
117.1. Company Overview
11.7.2. Service Portfolio
11.8. Precision NanoSystems
11.8.1. Company Overview
11.8.2. Service Portfolio
12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS
12.1. Chapter Overview
12.2. Ascendia Pharmaceuticals
12.2.1. Company Overview
12.2.2. Lipid Nanoparticle Technology Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. leon-nanodrugs
12.3.1. Company Overview
12.3.2. Lipid Nanoparticle Technology Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Pantherna Therapeutics
12.4.1. Company Overview
12.4.2. Lipid Nanoparticle Technology Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. TLC Biosciences
12.5.1. Company Overview
12.5.2. Lipid Nanoparticle Technology Portfolio
12.5.3. Recent Developments and Future Outlook
12.6. Acuitas Therapeutics
12.6.1. Company Overview
12.6.2. Service Portfolio
12.7. Integrated Nanotherapeutics
12.7.1. Company Overview
12.7.2. Service Portfolio
12.8. Matinas BioPharma
12.8.1. Company Overview
12.8.2. Service Portfolio
13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS
13.1. Chapter Overview
13.2. Avanti Polar Lipids
13.2.1. Company Overview
13.2.2. Service Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Corden Pharma
13.3.1. Company Overview
13.3.2. Service Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Fujifilm
13.4.1. Company Overview
13.4.2. Service Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. Merck
13.5.1. Company Overview
13.5.2. Service Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. FormuMax Scientific
13.6.1. Company Overview
12.6.2. Service Portfolio
13.7. Creative Biolabs
13.7.1. Company Overview
13.7.2. Service Portfolio
13.8. Fresenius Kabi
13.8.1. Company Overview
13.8.2. Service Portfolio
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Lipid Nanoparticles Services and Technologies: List of Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Type of Molecule
14.3.5. Analysis by Therapeutic Area
14.3.6. Analysis by Type of Partner
14.3.7. Most Active Players: Analysis by Number of Partnerships
14.3.8. Analysis by Geography
14.3.8.1. Intracontinental and Intercontinental Deals
14.3.8.2. International and Local Deals
15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Methodology
15.2. mRNA Drug Developers: Potential Strategic Partners in North America
15.3. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific
16. MAKE VERSUS BUY DECISION FRAMEWORK
16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
16.3.1. Scenario
16.3.2. Scenario
16.3.3. Scenario
16.3.4. Scenario
16.4. Concluding Remarks
17. CAPACITY ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
17.3.1. Analysis by Range of Installed Capacity
17.3.2. Analysis by Company Size
17.3.3. Analysis by Scale of Operation
17.3.4. Analysis by Location of Manufacturing Facility
17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
17.3.5. Concluding Remarks
18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion
19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations
20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2028, 2023 and 2035
20.3.1. Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.3.2. Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.7. Data Triangulation and Validation
21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
21.3.1. Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.2. Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.3. Peptides / Proteins, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.4. Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.4. Data Triangulation and Validation
22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
22.3.1. Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.2. Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.3. Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.4. Data Triangulation and Validation
23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TARGET THERAPEUTIC AREA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
23.3.1. Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.2. Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.3. Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.4. Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.5. Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.4. Data Triangulation and Validation
24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF END-USER
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
24.3.1. Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.2. Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.3. Other End-Users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.4. Data Triangulation and Validation
25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
25.3.1. North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.3. Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.4. Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation
26. CONCLUSION
27. EXECUTIVE INSIGHTS
27.1. Chapter Overview
27.2. LIPOSOMA
27.2.1. Company Snapshot
27.3. BIOVECTRA
27.3.1. Company Snapshot
27.4. OZ Biosciences
27.4.1. Company Snapshot
28. APPENDIX 1: TABULATED DATA
29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Lipids
5.3 Introduction to Lipid Nanoparticles
5.3.1. Types of Lipid Nanoparticles
5.3.1.1. Solid Lipid Nanoparticles
5.3.1.2. Nanostructured Lipid Carriers
5.3.2. Advantages of Lipid Nanoparticles
5.3.3. Applications of Lipid Nanoparticles in Pharmaceutical Industry
5.3.3.1. Cancer Treatment
5.3.3.2. Gene Therapy
5.3.3.3. Vaccine Development
5.3.3.4. Medical Imaging / Diagnostics
5.3.3.5. Additional Applications
5.4. Challenges Associated with Lipid Nanoparticle Manufacturing
5.5. Need for Outsourcing Lipid Nanoparticle Manufacturing
5.6. Concluding Remarks
6. LIPID NANOPARTICLES: SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Lipid Nanoparticle Manufacturing: List of Service Providers
6.2.1 Analysis by Year of Establishment
6.2.2 Analysis by Company Size
6.2.3 Analysis by Location of Headquarters
6.2.4 Analysis by Company Size and Location of Headquarters
6.2.5 Analysis by Location of Lipid Nanoparticle Manufacturing Facility
6.2.6 Analysis by Scale of Operation
6.2.7 Analysis by Type of Molecule Delivered
6.2.8 Analysis by Therapeutic Area
6.2.9 Analysis by Type of Additional Services Offered
7. LIPID NANOPARTICLES: TECHNOLOGY LANDSCAPE
7.1. Chapter Overview
7.2. Lipid Nanoparticle: Technology Landscape
7.2.1. Analysis by Type of Formulation Method
7.2.2. Analysis by Type of Molecule Delivered
7.2.3. Analysis by Compatible Dosage Form
7.2.4. Analysis by Routes of Administration
7.2.5. Analysis by Therapeutic Area
7.3. Lipid Nanoparticle Technologies: List of Technology Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Analysis by Business Model
7.3.6. Most Active Players: Analysis by Number of Technologies
8. OTHER TYPES OF LIPIDS: SERVICE PROVIDERS LANDSCAPE
8.1. Chapter Overview
8.2. Other Types of Lipids: List of Service Providers
8.2.1 Analysis by Year of Establishment
8.2.2 Analysis by Company Size
8.2.3 Analysis by Location of Headquarters
8.2.4 Analysis by Company Size and Location of Headquarters
8.2.5. Analysis by Location of Manufacturing Facility
8.2.6. Analysis by Scale of Operation
8.2.7 Analysis by Type of Lipid Manufactured
8.2.8. Analysis by Scale of Operation and Type of Lipid Manufactured
8.2.9. Analysis by Type of Product
8.2.10. Analysis by Type of Additional Services Offered
8.2.11. Analysis by Type of Product and Type of Additional Services Offered
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Lipid Nanoparticle Manufacturing Service Providers: Company Competitiveness Analysis
9.4.1. Company Competitiveness Analysis: Small Players
9.4.2. Company Competitiveness Analysis : Mid-sized Players
9.4.3. Company Competitiveness Analysis : Large and Very Large Players
10. TECHNOLOGY COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Lipid Nanoparticle Technologies: Competitiveness Analysis
10.4.1. Technology Competitiveness Analysis: Players based in North America
10.4.2. Technology Competitiveness Analysis: Players based in Europe and Asia-Pacific
11. COMPANY PROFILES: SERVICE PROVIDERS OF LIPID NANOPARTICLES
11.1. Chapter Overview
11.2. Curia
11.2.1. Company Overview
11.2.2. Service Portfolio
11.2.3. Recent Developments and Future Outlook
11.3. Emergent BioSolutions
11.3.1. Company Overview
11.3.2. Service Portfolio
11.3.3. Recent Developments and Future Outlook
11.4. EUROAPI
11.4.1. Company Overview
11.4.2. Service Portfolio
11.4.3. Recent Developments and Future Outlook
11.5. Evonik
11.5.1. Company Overview
11.5.2. Service Portfolio
11.5.3. Recent Developments and Future Outlook
11.6. Ardena
11.6.1. Company Overview
11.6.2. Service Portfolio
11.7. BIOVECTRA
117.1. Company Overview
11.7.2. Service Portfolio
11.8. Precision NanoSystems
11.8.1. Company Overview
11.8.2. Service Portfolio
12. COMPANY PROFILES: LIPID NANOPARTICLE TECHNOLOGY DEVELOPERS
12.1. Chapter Overview
12.2. Ascendia Pharmaceuticals
12.2.1. Company Overview
12.2.2. Lipid Nanoparticle Technology Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. leon-nanodrugs
12.3.1. Company Overview
12.3.2. Lipid Nanoparticle Technology Portfolio
12.3.3. Recent Developments and Future Outlook
12.4. Pantherna Therapeutics
12.4.1. Company Overview
12.4.2. Lipid Nanoparticle Technology Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. TLC Biosciences
12.5.1. Company Overview
12.5.2. Lipid Nanoparticle Technology Portfolio
12.5.3. Recent Developments and Future Outlook
12.6. Acuitas Therapeutics
12.6.1. Company Overview
12.6.2. Service Portfolio
12.7. Integrated Nanotherapeutics
12.7.1. Company Overview
12.7.2. Service Portfolio
12.8. Matinas BioPharma
12.8.1. Company Overview
12.8.2. Service Portfolio
13. COMPANY PROFILES: SERVICE PROVIDERS OF OTHER TYPES OF LIPIDS
13.1. Chapter Overview
13.2. Avanti Polar Lipids
13.2.1. Company Overview
13.2.2. Service Portfolio
13.2.3. Recent Developments and Future Outlook
13.3. Corden Pharma
13.3.1. Company Overview
13.3.2. Service Portfolio
13.3.3. Recent Developments and Future Outlook
13.4. Fujifilm
13.4.1. Company Overview
13.4.2. Service Portfolio
13.4.3. Recent Developments and Future Outlook
13.5. Merck
13.5.1. Company Overview
13.5.2. Service Portfolio
13.5.3. Recent Developments and Future Outlook
13.6. FormuMax Scientific
13.6.1. Company Overview
12.6.2. Service Portfolio
13.7. Creative Biolabs
13.7.1. Company Overview
13.7.2. Service Portfolio
13.8. Fresenius Kabi
13.8.1. Company Overview
13.8.2. Service Portfolio
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Lipid Nanoparticles Services and Technologies: List of Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Type of Molecule
14.3.5. Analysis by Therapeutic Area
14.3.6. Analysis by Type of Partner
14.3.7. Most Active Players: Analysis by Number of Partnerships
14.3.8. Analysis by Geography
14.3.8.1. Intracontinental and Intercontinental Deals
14.3.8.2. International and Local Deals
15. LIKELY PARTNER ANALYSIS
15.1. Chapter Overview
15.2. Methodology
15.2. mRNA Drug Developers: Potential Strategic Partners in North America
15.3. mRNA Drug Developers: Potential Strategic Partners in Europe and Asia-Pacific
16. MAKE VERSUS BUY DECISION FRAMEWORK
16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Lipid Nanoparticle Service Providers: Make versus Buy Decision Making Framework
16.3.1. Scenario
16.3.2. Scenario
16.3.3. Scenario
16.3.4. Scenario
16.4. Concluding Remarks
17. CAPACITY ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Installed Lipid Nanoparticle Contract Manufacturing Capacity
17.3.1. Analysis by Range of Installed Capacity
17.3.2. Analysis by Company Size
17.3.3. Analysis by Scale of Operation
17.3.4. Analysis by Location of Manufacturing Facility
17.3.4.1. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in North America
17.3.4.2. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Europe
17.3.4.3. Analysis of Installed Lipid Nanoparticle Contract Manufacturing Capacity in Asia-Pacific
17.3.5. Concluding Remarks
18. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion
19. GLOBAL LIPID NANOPARTICLE MANUFACTURING MARKET
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Global Lipid Nanoparticle Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.3.1. Scenario Analysis
19.3.1.1. Conservative Scenario
19.3.1.2. Optimistic Scenario
19.4. Key Market Segmentations
20. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF LIPID NANOPARTICLE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Lipid Nanoparticle, 2028, 2023 and 2035
20.3.1. Solid Lipid Nanoparticles, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.3.2. Nanostructured Lipid Carriers, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
20.7. Data Triangulation and Validation
21. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF MOLECULE DELIVERED
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of Molecule Delivered, 2018, 2023 and 2035
21.3.1. Nucleic Acids, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.2. Small Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.3. Peptides / Proteins, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.3.4. Other Molecules, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
21.4. Data Triangulation and Validation
22. LIPID NANOPARTICLE MANUFACTURING MARKET, BY COMPANY SIZE
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Lipid Nanoparticle Manufacturing Market: Distribution by Company Size, 2018, 2023 and 2035
22.3.1. Very Large and Large Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.2. Mid-sized Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.3.3. Small Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
22.4. Data Triangulation and Validation
23. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TARGET THERAPEUTIC AREA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Lipid Nanoparticle Manufacturing Market: Distribution by Target Therapeutic Area, 2018, 2023 and 2035
23.3.1. Infectious Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.2. Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.3. Blood Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.4. Rare Diseases, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.3.5. Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
23.4. Data Triangulation and Validation
24. LIPID NANOPARTICLE MANUFACTURING MARKET, BY TYPE OF END-USER
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Lipid Nanoparticle Manufacturing Market: Distribution by Type of End-user, 2018, 2023 and 2035
24.3.1. Pharmaceutical and Biotechnology Companies, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.2. Academic and Research Institutes, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.3.3. Other End-Users: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
24.4. Data Triangulation and Validation
25. LIPID NANOPARTICLE MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Lipid Nanoparticle Manufacturing Market: Distribution by Key Geographical Regions, 2018, 2023 and 2035
25.3.1. North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.2. Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.3. Asia-Pacific, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.3.4. Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
25.4. Data Triangulation and Validation
26. CONCLUSION
27. EXECUTIVE INSIGHTS
27.1. Chapter Overview
27.2. LIPOSOMA
27.2.1. Company Snapshot
27.3. BIOVECTRA
27.3.1. Company Snapshot
27.4. OZ Biosciences
27.4.1. Company Snapshot
28. APPENDIX 1: TABULATED DATA
29. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
